Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout
Executive Summary
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.
You may also be interested in...
Bayer Consolidates Next-Generation Gene Editing Focus With Mammoth Deal
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.
The Inside Story On How Bayer Swooped On NASDAQ-Bound Vividion
It has taken just seven weeks from a cold call to completion and the German major has got its hands on a prized asset in Vividion which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.
Bayer Bids To Be A Winner In Cell & Gene Therapy
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.